GTXI Key Statistics, Chart & Performance
The current stock price of GTXI is 1.2 null. In the past month the price increased by 4.35%. In the past year, price decreased by -93.78%.
GTXI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GTXI. When comparing the yearly performance of all stocks, GTXI is a bad performer in the overall market: 96.42% of all stocks are doing better.
GTXI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GTXI. The financial health of GTXI is average, but there are quite some concerns on its profitability.
GTXI Financial Highlights
Over the last trailing twelve months GTXI reported a non-GAAP Earnings per Share(EPS) of -1.8699999999999999. The EPS increased by 1.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -135.46% | ||
| ROE | -147.3% | ||
| Debt/Equity | 0 |
GTXI Forecast & Estimates
GTXI Ownership
About GTXI
Company Profile
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
Company Info
Gtx
17 W Pontotoc Ave. Suite 100
MEMPHIS TN 38103
CEO: Marc S. Hanover
Phone: 901-523-9700
Gtx / GTXI FAQ
What does GTXI do?
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
Can you provide the latest stock price for Gtx?
The current stock price of GTXI is 1.2 null.
Does GTXI stock pay dividends?
GTXI does not pay a dividend.
What is the ChartMill technical and fundamental rating of GTXI stock?
GTXI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for GTXI stock?
Gtx (GTXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).